Complex Regional Pain Syndromes
Conditions
Keywords
Complex Regional Pain Syndrome, Reflex Sympathetic Dystrophy, RSD, Chronic Pain, Ethosuximide, Zarontin, Anticonvulsant
Brief summary
Pain remains the most debilitating symptom for adult patients suffering from complex regional pain syndrome (CRPS). Most CRPS patients gain little to no relief from current painkillers. The purpose of this study is to evaluate the efficacy and safety of ethosuximide in search of much-needed adjunctive therapy to relieve the pain and suffering associated with CRPS.
Detailed description
This is a single centre, parallel-group, double-blind, randomized, placebo-controlled pilot clinical trial for adults suffering from complex regional pain syndrome (CRPS). Twelve (12) subjects diagnosed with CRPS will be enrolled and randomized to receive orally, either ethosuximide or placebo. If the maximum trial medication dosage (1500mg) is reached, the subject will be in the study for a maximum of 10 weeks from screening (Clinic Visit 1) to the end of the drug cessation period. The minimum period a subject could complete the study would be 4 weeks presuming they were not previously on any disallowed drugs and only found the 500mg dose tolerable.
Interventions
DRUGPlacebo
250mg matching placebo capsules
DRUGEthosuximide
500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
Sponsors
McGill University
McGill University Health Centre/Research Institute of the McGill University Health Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female, age ≥18 years old; * Diagnosis of Complex Regional Pain Syndrome (CRPS) using International Association for the Study of Pain criteria \>6 months; * Normal liver function (AST level \<3x normal level); * Normal kidney function (serum creatinine \<133µmol/L); * Full blood count, haematocrit \>38%; * Willing and able to give informed consent and of completing study questionnaires; * Stable (no change in past two months) but suboptimal pain pharmacotherapy (i.e. additional pain control felt by patient and physician to be necessary); * Able to attend research centre according to the visit schedule; * Women of child-bearing potential must be using a reliable form of contraception i.e. oral contraceptives, a barrier method (condom or diaphragm), intra-uterine device or abstinence.
Exclusion criteria
* Optimal response to opioids, antidepressants, anticonvulsants or anti- inflammatory medications; * Any history or indication of kidney or liver disease; * Any history of alcohol abuse; * Presence of diabetes; * Subjects taking other anti-epileptic drugs, including gabapentin, pregabalin, topiramate, phenytoin, carbamazepine, and oxcarbazepine; * Pregnancy (a serum bHCG pregnancy test will be performed as part of the initial blood panel); * Known or suspected allergy to succinimides, ethosuximide, methsuximide (Celontin®), phensuximide; * Any history of mental illness or disorder, which in the investigators opinion, interferes with the subjects ability to accurately report treatment response; * Participation in other clinical trial in the 30 days prior to enrolment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (500mg-1500mg per day) and Safety profile | up to 10 weeks | Primary outcomes will consist of the dose attained during the study and the safety (adverse event) profile. Maximum timeframe on study drug is 6 weeks. Adverse events will be collected up to one month after the trial period ends. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain Intensity Scores on the Visual Analogue Scale (VAS) | up to 7 weeks | Pain Intensity captured on Day 1 (First study visit post-disallowed drug cessation period) and 7 days after maximal-tolerated dose attained (Final Study Visit) |
| Pain Intensity Scores on the Numerical Rating Scale (NRS) | up to 5 weeks | Pain Intensity using the Numerical Rating Scale will be captured by telephone every week during dose titration period (Days 3 and 6). |
| Neuropathic Pain Symptom Inventory (NPSI) | up to 7 weeks | Day 1 (First study visit post-disallowed drug cessation period) and 7 days after maximal-tolerated dose attained (Final Study Visit) |
| Short Form 12v2 (SF-12v2) | up to 7 weeks | Quality of Life measured on Day 1 (First study visit post-disallowed drug cessation period) and 7 days after maximal-tolerated dose attained (Final Study Visit) |
| Short Form McGill Pain Questionnaire (SF-MPQ) | up to 7 weeks | Day 1 (First study visit post-disallowed drug cessation period) and 7 days after maximal-tolerated dose attained (Final Study Visit) |
Countries
Canada
Outcome results
None listed